Germany-based ITM Isotope Technologies Munich SE has secured an equity investment of €33 million from two financial groups in order to advance a radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumours, also known as islet cell tumours. The latest financing comes on top of an earlier €25 million investment, bringing the total sums raised by the company for product development up to €58 million.
The two newest investors are Indigenous Critical Infrastructure Fund Canada and a private equity group managed by Portland Investment Counsel Inc.